A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Presented here is ovarian tissue oocyte-in vitro maturation (OTO-IVM), an accessible technique within a medical assisted reproduction (MAR) laboratory offering realistic additional fertility preservation options to patients who need ovarian tissue cryopreservation.

Abstract

Mature oocyte vitrification is the standard of care to preserve fertility in women at risk of infertility. However, ovarian tissue cryopreservation (OTC) is still the only option to preserve fertility in women who need to start gonadotoxic treatment urgently or in prepubertal children. During ovarian cortex preparation for cryopreservation, medullar tissue is removed. Growing antral follicles reside at the border of the cortex-medullar interface of the ovary and are broken during this process, releasing their cumulus-oocyte complex (COC). By thoroughly inspecting the medium and fragmented medullar tissue, these immature cumulus-oocyte complexes can be identified without interfering with the OTC procedure. The ovarian tissue-derived immature oocytes can be successfully matured in vitro, creating an additional source of gametes for fertility preservation. If OTC is performed within or near a medical assisted reproduction laboratory, all necessary in vitro maturation (IVM) and oocyte vitrification tools can be at hand. Furthermore, upon remission and child wish, the patient has multiple options for fertility restoration: ovarian tissue transplantation or embryo transfer after the insemination of vitrified/warmed oocytes. Hence, ovarian tissue oocyte-in vitro maturation (OTO-IVM) can be a valuable adjunct fertility preservation technique.

Introduction

Fertility preservation (FP) options for women planned for gonadotoxic treatment, sex-reassignment therapy, or women who have a genetic predisposition for premature ovarian failure, depend on the health and age of the patient, available timeframe, type of treatment, patient's preference, and FP procedures available at the fertility center of choice. Vitrification of mature oocytes obtained after ovarian stimulation with gonadotropins and oocyte retrieval in a medical assisted reproduction (MAR) laboratory cycle is considered the preferred option for FP1,2. However, for prepubertal girls, women in whom the urgent start of gonadotoxic treatment or gonadectomy is required, or women with a high risk of permanent amenorrhea due to gonadotoxic treatment, a cycle of ovarian stimulation with gonadotropins is not possible, and ovarian tissue cryopreservation (OTC), which is an accepted and valid technique for FP1,2,3, is the only option. The goal of OTC is to cryopreserve thousands of dormant primordial follicles in the ovarian cortex tissue, which can resume growth after the transplantation of frozen/thawed tissue onto the remaining ovary or in a peritoneal pocket after the careful screening of minimal residual disease in representative tissue fragments.

In order to obtain cortical fragments of 1-2 mm thickness suitable for cryopreservation, the soft medullar tissue needs to be removed. This medullar tissue typically entails growing follicles in various stages of development that escape the stiff ovarian cortex to allow for their growth and expansion4. For many years, several labs have been investigating the potential of these oocytes recovered from follicles residing in the remnant medullar tissue after ovarian cortical fragment preparation using in vitro maturation (IVM)5,6,7, referred to as ovarian tissue oocyte IVM (OTO-IVM). Antral follicles, even those less than 6 mm in diameter, contain immature oocytes surrounded by cumulus cells that can mature, fertilize, and develop into healthy babies using an IVM system8,9. IVM is considered the standard of care for women at risk for ovarian hyperstimulation syndrome (OHSS), such as polycystic ovary syndrome (PCOS) patients. However, in the field of FP, there are limited data available for IVM in cases with a contraindication for ovarian stimulation; IVM of oocytes collected transvaginally is still considered innovative, and OTO-IVM is considered experimental2,10. That said, the reports of the first live births after OTO-IVM11,12,13 highlight the potential of using OTO-IVM as an add-on technique when OTC is required for FP in patients14.

This study provides technical details to adopt OTO-IVM in the MAR laboratory and illustrates the results obtained in a single center.

Protocol

The present study on OTO-IVM has been approved by the local Ethical Committee of UZ-Brussels (addendum of project 2008/068 and project 2022/303). All patients signed written informed consent. Each patient was individually assessed by a reproductive medicine specialist physician, navigator nurse, and the referring oncologist to compose the optimal FP treatment plan, taking into account the patient's preferences14. In short, patients eligible for OTC are in urgent need of FP and are less than 36 years of age14. To combine OTC with OTO-IVM, chemo- or radiotherapy cannot have been administered in the 6 months preceding OTC.

1. Laboratory environment and personnel

  1. Perform OTC in a Class A laminar flow cabinet.
  2. Perform OTC with two operators: one working aseptically in the laminal flow cabinet, and a second cleaning all non-sterile materials with a bactericide and sporicide decontaminant spray and handing over materials and supplies aseptically to the first operator. Process the ovarian cortex on a benchtop cooler lid (Β± 4 Β°C).
  3. Perform the cumulus-oocyte complex (COC) search in a second laminar flow cabinet with a stereomicroscope in a MAR lab on a heated stage (37 Β°C).
  4. Perform retrieval of the COC from the medullar remnants (sections 3 and 4) and initiate the IVM process (section 5). This is done by a third operator.

2. Media preparation

NOTE: Five types of media are used for this procedure (detailed below): OTC handling medium, OTC freezing medium, Search medium, LAG medium, and IVM medium. When preparing media, work aseptically in the flow cabinet, as detailed in section 1. Use new, unopened reagents for every procedure and maintain the sterility of all disposables used to ascertain the sterility of the produced media.

  1. OTC handling medium
    1. Supplement Leibovitz's L15 medium with 4 mg/mL human serum albumin (HSA), 100 U/mL penicillin, and 100 Β΅g/mL streptomycin (see Table of Materials).
    2. Keep the OTC handling medium refrigerated until use (for a maximum of 2 days).
      NOTE: Use OTC handling medium to rinse and process the ovarian tissue and use it cold (0-4 Β°C).
  2. OTC freezing medium
    1. Supplement Leibovitz's L15 medium with 1.5 M dimethyl sulfoxide (DMSO) and 4 mg/mL HSA.
    2. Keep the OTC freezing medium refrigerated until use (for a maximum of 2 days).
  3. Search medium
    NOTE: The Search medium (a HEPES-buffered medium for oocyte handling) is commercially available (see Table of Materials) and ready to use. Use the Search medium to rinse the filter and collect the COC while searching for COCs in between the medulla fragments (section 4).
    1. Fill six 14 mL round-bottom, sterile tubes with 6 mL of Search medium.
    2. Prepare a 4-well dish with 500 Β΅L of Search medium covered with 350 Β΅L of oil (see Table of Materials).
    3. Heat the tubes and the 4-well dish at 37 Β°C for at least 1 h prior to the arrival of the ovarian tissue. HEPES-buffered media do not require CO2 incubation.
  4. LAG medium
    NOTE: The commercially available IVM system (see Table of Materials) comprises two different media: LAG medium and IVM medium, which needs to be supplemented as detailed below. LAG medium is used to rinse the COCs, but can also be used for a 2-3 h incubation period preceeding IVM in IVM medium, as suggested by the insert of the IVM system.
    1. Use the commercially available, ready-to-use LAG medium (see Table of Materials).
  5. IVM medium
    1. Supplement commercially available IVM medium with 10 mg/mL HSA, 75 mIU/mL follicle stimulating hormone (FSH), and 100 mIU/mL human chorionic gonadotropin (hCG).
    2. Prepare a 4-well culture dish with one well of LAG medium and three wells of supplemented IVM medium: 500 Β΅L of medium covered with 350 Β΅L of oil overlay.
    3. Equilibrate the dish overnight in an incubator at 37 Β°C in 6% CO2 and 20% O2,Β the optimal environment for IVM culture.

3. Ovarian cortex preparation

NOTE: Laparoscopic whole ovary removal was performed as described by Jadoul et al.15.

  1. Upon arrival of the ovary in the laboratory, wash the ovary in the OTC handling medium (step 2.1) twice by transferring the ovary into a 100 mm Petri dish with the OTC handling medium.
  2. With a scalpel, cut open the ovary in half longitudinally (Figure 1A).
  3. Make several incisions in the medullar tissue both vertically and horizontally with a fresh scalpel. Avoid damaging the cortex. Pierce the firm antral follicles of various sizes within the medulla gently with the scalpel to release the follicular fluid in the OTC handling medium.
  4. Pare down the soft medulla tissue with surgical scissors (Figure 1B). This procedure may take several minutes.
  5. Put the ovarian shell in a new dish with fresh OTC handling medium during the trimming process.
  6. Transfer the dish with medullar fragments and released follicular fluid (Figure 1C) to the second flow cabinet to start the search for COCs.
  7. Repeat steps 3.4 to 3.6 until the desired thickness (1-2 mm) of the cortex tissue is obtained.
  8. Slice the cortex into pieces of approximately 8 mm x 5 mm.
  9. Incubate the pieces 3x consecutively for 10 min in approximately 25 mL of OTC freezing medium (step 2.2) in 100 mm Petri dishes.
  10. Place one piece in 800 Β΅L of OTC freezing medium in a cryovial.
  11. Cryopreserve the ovarian tissue using a slow freezing protocol in a cryochamber controlled by a temperature controller (see Table of Materials): from 4 Β°C to -7 Β°C at -2 Β°C/min, manual seeding at -7 Β°C, from -7Β° C to -40 Β°C at -0.3 Β°C/min, from -40 Β°C to -100 Β°C at -10 Β°C/min, and at -100 Β°C plunge the cryovials in liquid nitrogen and store them.

4. Search for COCs

  1. Prepare the laminar flow cabinet for the COC search.
    1. Warm 60 mm culture dishes on the heated stage under the stereomicroscope in the laminar flow cabinet.
    2. Put the 14 mL tubes with 6 mL of preheated Search medium (step 2.3.1) in a heated block, and the preheated 4-well dish with Search medium on the heated stage under the microscope in the laminar flow cabinet.
    3. Place a sterile filter (cell strainer, 70 Β΅m mesh size; see Table of Materials) bottom-down in a culture dish.
    4. Take a 290-310 Β΅m glass capillary for use: do not use smaller capillaries than 290-310 Β΅m, in order to avoid damage to the oocyte-cumulus cell connectivity.
    5. Ensure 1 mL filter tips and a 1 mL pipet are available.
  2. Take the first dish with medullar fragments from the OTC laminar flow cabinet (4 Β°C) and put the dish on the heated stage (37 Β°C) in the IVM laminar flow cabinet as soon as possible.
    NOTE: The first dish of medullar fragments and follicular fluid might be contaminated with blood from blood-filled ovulated follicles or the vasculature of the ovary itself. Red blood cells blur clear vision and complicate the search for COCs. The contaminated medium must be removed to wash away the red blood cells (see step 4.3).
  3. Remove the blood cell contamination by following the steps below.
    1. Pipet 2 mL of Search medium over the filter membrane (70 Β΅m cell strainer) to wet the membrane and put the dish, which captured the medium, aside on the heated stage.
    2. Flip the filter upside-down and place it with the handle against the rim of a new culture dish, creating a slope with the bottom of the filter.
    3. Collect blood-contaminated medium in between medullar fragments using a 1 mL tip and blow it gently over the filter membrane (Figure 1D) to capture the COCs present in the contaminated medium.
    4. Repeat step 4.3.3 until most of the blood-contaminated medium is removed.
    5. Pour fresh Search medium over the medullar fragments immediately to keep the COC suspended in the culture medium at all times.
    6. Rinse the sloped filter membrane gently with 2 mL of Search medium to rinse away red blood cells on the filter membrane.
    7. Place the filter bottom-down in a new dish and pour 3-4 mL of Search medium into the filter to expel the COC from the filter membrane into the medium that fills the dish. Remove the filter. To ensure that the filter membrane does not dry out (and any possible COCs that are not yet expelled from it), immerse the filter bottom-down in the first dish, which was used to wet the filter for the first time.
    8. Immediately examine the expelled medium for COCs by visual inspection under a stereo microscope with a magnification of 10x-50x. Search for clear translucent oocytes with a rim of dark, compact surrounding cumulus cells (Figure 1E). Swirl the medium in the dish and examine the medium again.
    9. Rinse the filter a second time in a new dish and examine the expelled medium for COCs.
    10. Examine the medium in the dish where the filter is immersed for the remaining COCs.
    11. Transfer COCs with a glass capillary to the 4-well dish containing the Search medium (Figure 1E). Keep the dishes on the heated stage at all times.
  4. Search in between the medullar fragments for COCs after removing the contaminating blood cells from the dish with medullar fragments and replenishing the dish with clear Search medium. Use the glass capillary to move around the medullar fragments and swirl the medium in the dish in order to find COCs. Pull apart large medullar fragments with tuberculin needles on a 1 mL syringe if the presence of an oocyte is suspected.
  5. Collect all intact COCs in the 4-well dish with Search medium.
    ​NOTE: In a typical OTC procedure, cortex tissue is pared down from the medulla using three consecutive 100 mm dishes, where the ovarian shell is moved to a new dish with fresh medium and where the remnants are transferred to the IVM flow for COC search. Usually, only the first dish requires the removal of blood cells; in the second and third dishes, fewer medullar fragments are present, and COC search is performed directly in between fragments and in the medium.

5. IVM of COCs

  1. Rinse the COCs in a clean well with Search medium.
  2. Move the pre-equilibrated IVM culture dish (the 4-well dish that contains one well of LAG medium and three wells of IVM medium) from the incubator to the heated stage in the IVM flow cabinet.
  3. Label the IVM culture dish containing COCs with patient information.
  4. Rinse the COCs in LAG medium (2-3 s) and place them in one of the three wells with supplemented IVM medium. Culture the COCs in groups of approximately 10 COCs per well. Omit naked oocytes-oocytes devoid of attached cumulus cells-from the culture, as they are known to have severely compromised developmental potential.
  5. Place the dish in an incubator at 37 Β°C, 6% CO2, and 20% O2 for 30 h.

6. Handling mature oocytes

  1. Strip oocytes of their surrounding cumulus cells by brief exposure to 80 IU of hyaluronidase (see Table of Materials) and gentle mechanical pipetting after 30 h of IVM.
  2. Identify mature oocytes by the extrusion of the first polar body.
  3. Vitrify or inseminate the mature oocytes, depending on the patient's preference.
    NOTE: If the maturation check after 30 h of IVM falls outside the acceptable working hours, the IVM duration can be shortened to 28 h or extended up to 42 h. If only a few mature oocytes are obtained after 30 h, immature oocytes can be cultured additionally overnight in the original IVM well, devoid of cumulus cells, and used the next morning for vitrification or intracytoplasmic sperm injection (ICSI) when mature.

Results

Over the past decade, 98 patients undergoing oophorectomy or ovarian biopsy for OTC were also offered OTO-IVM. The results presented here are an update of the clinical program as published before7,13. Immature oocytes obtained during ovarian tissue processing were matured in vitro predominantly for 30 h. However, a more flexible maturation time was allowed for practical reasons or because of low maturation, ranging from 28-42 h. Patients opted predominan...

Discussion

The priority of the FP procedure is always to manipulate and freeze the ovarian cortex according to the standard operating protocol that has been validated in the clinic. A drawback in FP is the absence of a standard protocol available in the published literature regarding OTC and OTO-IVM. It is difficult to assess the efficiency and validity of the techniques and adaptations since there is a large time gap between freezing/vitrification and thawing/warming in a clinical setting. If changes to the OTC protocol are made t...

Disclosures

The authors have no competing financial interests.

Acknowledgements

This work was conducted at the IVF laboratory of Brussels IVF, Universitair Ziekenhuis of VUB, Brussels. The authors would like to thank all Brussels IVF laboratory team members for their high skills, accuracy, and flexibility needed to establish a fertility preservation unit within a MAR laboratory.

Materials

NameCompanyCatalog NumberComments
1000 Β΅L filter tipsEppendorf/VWR International613-6780COC search
Benchtop CoolerFisher Scientific15-350-54Benchtop Cooler lid is used to prepare the tissue, Benchtop Cooler tube holder to keep cryovials with freezing medium cooled
Corning Cell culture dish, non-treated, 100 mmCorning/VWR International430591Dish for ovarian tissue preparation
CryoSure-DMSOWAK Chemicals0482Cryoprotectant for ovarian tissue cryopreservation
CumulaseOrigio/CooperSurgical16125000Arecombinant human hyaluronidase enzyme for cumulus cell removal after IVM
Decontamination spray: SuproxMedipure LTDMP016Desinfectant solution for aseptic handling with bactericide and sporicide action
Disposable scalpelsSwann-Morton0511Ovarian tissue preparation
Falcon 14 mL Round Bottom Polystyrene Test Tube, with Snap Cap, SterileFalcon/VWR InternationalBDAA352057Medium containerΒ 
Falcon Cell strainer 70 Β΅mFalcon/VWR International352350Filter for elimination of red blood cell contamination and COC search
Freeze control Ampoule Cryochamber and Temperature ControllerCryologicCL-8800iΒ Β  CC60ASSlow freezing machine
FSH: Menopur 75 IUFerringBE197504Follicle Stimulating Hormone : Supplement for IVM medium
Handling pipette 290-310 Β΅mVitrolife15538COC search: gentle transfer of COC without damaging oocyte-cumulus cell connectivity
hCG: Brevactid 5000 IEFerring5008001036Human Chorionic Gonadotropin : Supplement for IVM medium
High security tubeCryoBioSystem022252cryovial, heat-sealed for safe cryostorage
HSA-solutionVitrolife10064Human serum Albumin: supplement for IVM medium
Leibovitz's L-15 mediumLife Technologies Europe31415-029Handling medium for ovarian tissue preparation
MediCult IVM systemOrigio/CooperSurgical82214010medium for IVM containing both LAG and IVM medium. IVM medium needs to be supplemented as detailed in the protocol
METZENBAUM fino scissors 140 mmChirurgical MaintenanceVIZ08280314Medium size scissors for initial medulla removal
Nunc 4-well dishes for IVFNunc/VWR International144444COC collection during COC search and IVM culture
Nunc Invitro fertilization Petri Dish with Vented Lid, 60 mm, Non-Pyrogenic, SterileThermo Scientific/VWRNUNC150270Dish for COC search
Oocyte handling medium : Flushing Medium with heparinOrigio/CooperSurgical10765060Search medium for COC search
OvoilVitrolife10029oil for IVM culture
Penicillin/Streptomicin mixLife Technologies Europe15140-148Supplement for OTC handling medium
Scissors, curved, 150 mm long, 20 mm bladeChirurgical MaintenanceVIREBST999-SCSmall size scissors for residual medulla removal

References

  1. Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertility and Sterility. 112 (6), 1022-1033 (2019).
  2. Anderson, R. A., et al. ESHRE guideline: female fertility preservation. Human Reproduction Open. 2020 (4), (2020).
  3. Karavani, G., et al. Chemotherapy-based gonadotoxicity risk evaluation as a predictor of reproductive outcomes in post-pubertal patients following ovarian tissue cryopreservation. BMC Women's Health. 21 (1), 201 (2021).
  4. Fiorentino, G., et al. Biomechanical forces and signals operating in the ovary during folliculogenesis and their dysregulation: implications for fertility. Human Reproduction Update. 29 (1), 1-23 (2023).
  5. Revel, A., et al. Oocyte collection during cryopreservation of the ovarian cortex. Fertility and Sterility. 79 (5), 1237-1239 (2003).
  6. Fasano, G., Moffa, F., Dechène, J., Englert, Y., Demeestere, I. Vitrification of in vitro matured oocytes collected from antral follicles at the time of ovarian tissue cryopreservation. Reproductive Biology and Endocrinology. 9, 150 (2011).
  7. Segers, I., et al. In vitro maturation (IVM) of oocytes recovered from ovariectomy specimens in the laboratory: a promising "ex vivo" method of oocyte cryopreservation resulting in the first report of an ongoing pregnancy in Europe. Journal of Assisted Reproduction and Genetics. 32 (8), 1221-1231 (2015).
  8. Guzman, L., et al. Developmental capacity of in vitro-matured human oocytes retrieved from polycystic ovary syndrome ovaries containing no follicles larger than 6 mm. Fertility and Sterility. 98 (2), e1-2 (2012).
  9. Mackens, S., et al. Outcome of in-vitro oocyte maturation in patients with PCOS: does phenotype have an impact. Human Reproduction. 35 (10), 2272-2279 (2020).
  10. Practice Committees of the American Society for Reproductive Medicine, the Society of Reproductive Biologists and Technologists, and the Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion. Fertility and Sterility. 115 (2), 298-304 (2021).
  11. Prasath, E. B., et al. First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient. Human Reproduction. 29 (2), 276-278 (2014).
  12. Uzelac, P. S., Delaney, A. A., Christensen, G. L., Bohler, H. C. L., Nakajima, S. T. Live birth following in vitro maturation of oocytes retrieved from extracorporeal ovarian tissue aspiration and embryo cryopreservation for 5 years. Fertility and Sterility. 104 (5), 1258-1260 (2015).
  13. Segers, I., et al. Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes. Human Reproduction. 35 (9), 2026-2036 (2020).
  14. Delattre, S., et al. Combining fertility preservation procedures to spread the eggs across different baskets: a feasibility study. Human Reproduction. 35 (11), 2524-2536 (2020).
  15. Jadoul, P., et al. Laparoscopic ovariectomy for whole human ovary cryopreservation: technical aspects. Fertility and Sterility. 87 (4), 971-975 (2007).
  16. Vilela, J. d. M. V., Dolmans, M. M., Amorim, C. A. Ovarian tissue transportation: a systematic review. Reproductive Biomedicine Online. 42 (2), 351-365 (2021).
  17. Vanhoutte, L., Cortvrindt, R., Nogueira, D., Smitz, J. Effects of chilling on structural aspects of early preantral mouse follicles. Biology of Reproduction. 70 (4), 1041-1048 (2004).
  18. Arav, A., Zvi, R. Do chilling injury and heat stress share the same mechanism of injury in oocytes. Molecular and Cellular Endocrinology. 282 (1-2), 150-152 (2008).
  19. Nikiforov, D., et al. Improving the maturation rate of human oocytes collected ex vivo during the cryopreservation of ovarian tissue. Journal of Assisted Reproduction and Genetics. 37 (4), 891-904 (2020).
  20. Vuong, L. N., et al. Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics. 37 (2), 347-357 (2020).
  21. Kirillova, A., et al. Improved maturation competence of ovarian tissue oocytes using a biphasic in vitro maturation system for patients with gynecological malignancy: a study on sibling oocytes. Journal of Assisted Reproduction and Genetics. 38 (6), 1331-1340 (2021).
  22. Segers, I., et al. In Vitro Maturation (IVM) culture conditions: the effect of oxygen tension and medium volume. Human Reproduction. 32, 126-127 (2017).
  23. De Munck, N., Santos-Ribeiro, S., Stoop, D., Van de Velde, H., Verheyen, G. Open versus closed oocyte vitrification in an oocyte donation programme: a prospective randomized sibling oocyte study. Human Reproduction. 31 (2), 377-384 (2016).
  24. Anderson, R. A., McLaughlin, M., Wallace, W. H. B., Albertini, D. F., Telfer, E. E. The immature human ovary shows loss of abnormal follicles and increasing follicle developmental competence through childhood and adolescence. Human Reproduction. 29 (1), 97-106 (2014).
  25. Karavani, G., et al. Age-dependent in vitro maturation efficacy of human oocytes-is there an optimal age. Frontiers in Cell and Developmental Biology. 9, 667682 (2021).
  26. Bourg, M., et al. Is in vitro maturation of oocytes retrieved ex vivo from ovarian tissue an effective fertility preservation technique in the presence of organic ovarian cysts. European Journal of Obstetrics and Gynecology and Reproductive Biology. 281, 87-91 (2023).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Ovarian Tissue CryopreservationOocyte VitrificationFertility PreservationIn Vitro MaturationCumulus oocyte ComplexFertility RestorationOvarian CortexMedullary TissueAntral FolliclesGonadotoxic Treatment

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright Β© 2025 MyJoVE Corporation. All rights reserved